References
1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A
review. Clinical immunology. 2020:108427.
2. Poyiadji N, Cormier P, Patel PY, et al. Acute pulmonary embolism and
COVID-19. Radiology. 2020;297(3):E335-E338.
3. Kerget B, Akgun M, Dogan N. Atypical presentation of COVID-19: Acute
renal failure. The Eurasian Journal of Medicine. 2020;52(2):224.
4. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2
variants and expression as candidates to sex and country differences in
COVID-19 severity in Italy. 2020.
5. Ichimura T, Mori Y, Aschauer P, et al. KIM-1/TIM-1 is a Receptor for
SARS-CoV-2 in Lung and Kidney. medRxiv. 2020.
6. Yang C, Zhang Y, Chen H, et al. Kidney injury molecule-1 is a
potential receptor for SARS-CoV-2. bioRxiv. 2020.
7. Azam TU, Shadid HR, Blakely P, et al. Soluble Urokinase Receptor
(SuPAR) in COVID-19–Related AKI. Journal of the American Society
of Nephrology. 2020;31(11):2725-2735.
8. D’Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for
the uPA/uPAR system. Drug discovery today. 2020;25(8):1528-1534.
9. Hamie L, Daoud G, Nemer G, et al. SuPAR, an emerging biomarker in
kidney and inflammatory diseases. Postgraduate medical journal.2018;94(1115):517-524.
10. Sjoding MW, Hofer TP, Co I, Courey A, Cooke CR, Iwashyna TJ.
Interobserver reliability of the Berlin ARDS definition and strategies
to improve the reliability of ARDS diagnosis. Chest.2018;153(2):361-367.
11. Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel
coronavirus (COVID-19) epidemics, the newest and biggest global health
threats: what lessons have we learned? International journal of
epidemiology. 2020;49(3):717-726.
12. He R, Lu Z, Zhang L, et al. The clinical course and its correlated
immune status in COVID-19 pneumonia. Journal of Clinical
Virology. 2020;127:104361.
13. Kerget B, Kerget F, Koçak AO, et al. Are serum interleukin 6 and
surfactant protein D levels associated with the clinical course of
COVID-19? Lung. 2020;198(5):777-784.
14. Kerget B, Kerget F, Aksakal A, Aşkın S, Sağlam L, Akgün M.
Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels
in COVID‐19 patients with macrophage activation syndrome and acute
respiratory distress syndrome. Journal of Medical Virology. 2020.
15. Luther T, Bülow‐Anderberg S, Larsson A, et al. COVID‐19 patients in
intensive care develop predominantly oliguric acute kidney injury.Acta Anaesthesiologica Scandinavica. 2020.
16. Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and
MERS-COV: a comparative overview. Infez Med. 2020;28(2):174-184.
17. Wu C-Z, Chang L-C, Lin Y-F, et al. Urokinase plasminogen activator
receptor and its soluble form in common biopsy-proven kidney diseases
and in staging of diabetic nephropathy. Clinical biochemistry.2015;48(18):1324-1329.
18. Van Oort PM, Bos LD, Póvoa P, et al. Soluble urokinase plasminogen
activator receptor for the prediction of ventilator-associated
pneumonia. ERJ open research. 2019;5(1).
19. Tsai P-K, Tsao S-M, Yang W-E, Yeh C-B, Wang H-L, Yang S-F. Plasma
soluble urokinase-type plasminogen activator receptor level as a
predictor of the severity of community-acquired pneumonia.International journal of environmental research and public
health. 2019;16(6):1035.
20. Gumus A, Altintas N, Cinarka H, et al. Soluble urokinase-type
plasminogen activator receptor is a novel biomarker predicting acute
exacerbation in COPD. International journal of chronic obstructive
pulmonary disease. 2015;10:357.
21. Guthoff M, Wagner R, Randrianarisoa E, et al. Soluble urokinase
receptor (suPAR) predicts microalbuminuria in patients at risk for type
2 diabetes mellitus. Scientific reports. 2017;7(1):1-7.
22. Theilade S, Lyngbaek S, Hansen T, et al. Soluble urokinase
plasminogen activator receptor levels are elevated and associated with
complications in patients with type 1 diabetes. Journal of
internal medicine. 2015;277(3):362-371.
23. Eugen‐Olsen J, Ladelund S, Sørensen LT. Plasma su PAR is lowered by
smoking cessation: a randomized controlled study. European journal
of clinical investigation. 2016;46(4):305-311.
24. Okulu E, Arsan S, Akin IM, et al. Serum levels of soluble urokinase
plasminogen activator receptor in infants with late‐onset sepsis.Journal of clinical laboratory analysis. 2015;29(5):347-352.
25. Hoenigl M, Raggam RB, Wagner J, et al. Diagnostic accuracy of
soluble urokinase plasminogen activator receptor (suPAR) for prediction
of bacteremia in patients with systemic inflammatory response syndrome.Clinical biochemistry. 2013;46(3):225-229.
26. Donadello K, Scolletta S, Covajes C, Vincent J-L. suPAR as a
prognostic biomarker in sepsis. BMC medicine. 2012;10(1):1-9.